FATE · Fate Therapeutics Inc

Track FATE — free

$2.57 +0.05 (+1.98%) At close · Aug 14

Market Cap

$307.94M

119.82M

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 13, 2026

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Strong Sentiment Bearish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 14.3 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +58%

above

Price vs 50-day avg +3%

above

RSI (14) 49

neutral

MACD trend Negative

52-week position 75%

mid-range

Volume (OBV) Bullish div.

accumulating

Momentum

relative strength

Strong

1-month return −8%

trailing

6-month return +70%

trailing

YTD return +162%

this year

Relative strength +56%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Distributing

-4% holders QoQ · +29 funds added

Insider flow Distributing

Net -$306.1K over 90 days · 100% sells

Short interest Rising

6.41% of float · ▲ +5.0% MoM · 4.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

152 holders — mid 3-yr range

Squeeze score 60

elevated · 0–100

Fundamentals

Fair

Revenue growth −51%

Y/Y

EPS growth +30%

Y/Y

Free cash flow $-112.0M

Balance sheet $31.7M

net cash

Quant / Vol

risk profile

Very High

Volatility 96%

annualized · 1-yr

Max drawdown −42%

past year

ATR 8.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Prior guidance period ended · from the Earnings Call filed Mar 31, 2024

Cash and cash equivalents and investments · end of the year at least $270M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+58% Bullish

Price vs 50-day avg

+3% Bullish

RSI (14)

49 Neutral

MACD trend

Negative Bearish

52-week position

75% Neutral

Volume (OBV)

Bullish div. Bullish

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Distributing

-4% holders QoQ · +29 funds added

Insider flow Distributing

Net -$306.1K over 90 days · 100% sells

Short interest Rising

6.41% of float · ▲ +5.0% MoM · 4.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

152 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $3 · 75% Range high $3

vs 200-day avg +58% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Cash, cash equivalents, and investments	$205M	Full Year 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
FATE Fate Therapeutics Inc this stock	$307.94M	+162.2%	-51.2%	—	6.4%
ONC BeOne Medicines Ltd.	$513.62B	+14.4%	+22179.2%	789.7	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$128.19B	+11.6%	+46.2%	29.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$82.72B	+4.1%	+20.8%	19.9	3.3%
ARGX Argenx SE	$52.94B	+1.2%	—	—	2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

152

% held: 60.0%
Net QoQ: -2.4M sh
Top holder: Redmile Group, LLC

Held Float

View

Held by Funds

Fund positions

132

View

Short & Settlement

Short Interest Rising

Shares short

7.7M

Days to cover: 4.6d
Change: +364.1K sh

View

Short Volume

Short vol %

45%

As of: Aug 14, 2026

Short Total

View

Fails to Deliver

FTD shares

4.4K

Value: $13.4K
As of: Jul 14, 2026

View

Off-Exchange

Off-exchange %

42.3%

Week of: Jul 6, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$306.1K

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Congressional Trades Sell

Member

Daniel Goldman

Amount: $1.0K–$15.0K
Traded: Jan 31, 2023

View

Financials

Revenue (FY)

$6.6M

Net income (FY): $-136.3M
EPS diluted: $-1.15

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 13, 2026
This year: 9

View

Proposed Sales

Value

$95.4K

Shares: 38.8K
Filed: Aug 4, 2026

View

Exempt Offerings

Offering

$50.0M

Filed: Jul 6, 2020

View

Earnings & Events

Earnings Calls

Last call

May 9, 2024

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
FATE	-8.2%	-7.6%	+70.2%	+4.9%	+162.2%
SPY	+0.4%	+4.5%	+13.8%	+3.9%	+13.9%
vs SPY	-8.6%	-12.0%	+56.4%	+1.0%	+148.4%

Key facts CIK 1434316 CUSIP 31189P102 13F (30d) 145 filings 144 filers Visit website Investor relations

FATE · Fate Therapeutics Inc

Price & Indicators

Up next

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance